Integrating UPLC‐MS/MS Bioinformatics and In Vivo Experiments Validation to Elucidate the Mechanism of Wenzi Jiedu Decoction in Suppressing Colorectal Cancer
Phytochemical Analysis · 2025
DOI: 10.1002/pca.3495 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytochemical Analysis, 2025. Verfasst von Tianqing Sang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Traditional Chinese Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Drugs, Chinese Herbal, Tandem Mass Spectrometry, Computational Biology. Die Arbeit nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Objectives
We used ultra‐performance liquid chromatography tandem mass spectrometry (UPLC‐MS/MS), bioinformatics, and in vivo experiments to study the anti‐colorectal cancer (CRC) effects of Wenzi Jiedu Decoction (WJD).
Methods
Detected the main components of WJD by UPLC‐MS/MS. Obtained WJD targets and CRC targets through the open source database. Analyzed the WJD‐CRC targets from a macro perspective by PPI, GO, and KEGG analyses. Validated bioinformatics findings by molecular docking and animal experiments.
Results
This study obtained 91 active compounds and 240 targets of WJD. Intersection with CRC genes (GSE32323 388 DEGs, GSE 215510 1253 DEGs), 36 WJD‐CRC common targets were obtained. PPI and enrichment analyses indicated WJD exerted anti‐CRC effects mainly through the chemokine signaling pathway and apoptosis. Quercetin, Luteolin, Kaempferol, Formononetin, Stigmasterol, and Hederagenin were the main compounds of WJD. CXCL8, BCL‐2, BAX, BCL2L1, CASP3, AKT1, and TP53 were the core targets of WJD‐CRC. Bulk molecular docking showed that core WJD compounds had good docking activity with WJD‐CRC targets. Animal experiments had shown the tumor inhibition rate of the WJD group was 36.53%. WJD could regulate the ratio of CD4+, CD8+, and CD4+/CD8+, reduce the expression of CXCL8, and BCL‐2, and increase the expression of BAX.
Conclusions
This study indicated that the potential mechanism of WJD in the prevention and treatment of CRC had the characteristics of the multi‐target, multi‐path, and multi‐system mechanisms, which were mainly related to the regulation of chemokines and the promotion of apoptosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Traditional Chinese Medicine, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
- Institute of Oncology, the First Clinical Medical College, Jiangsu Collaborative Innovation Center of Traditional Chinese Medicine Prevention and Treatment of Tumor, Nanjing University of Chinese Medicine, Nanjing, Jian…
- Department of Radiology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
- Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
ORCID-Profile: Tianqing Sang, Hongguang Zhou
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Sang, T., Liang, A., Zhou, H., Qiu, W., Shi, L., & Zhou, H. (2025). Integrating UPLC‐MS/MS Bioinformatics and In Vivo Experiments Validation to Elucidate the Mechanism of Wenzi Jiedu Decoction in Suppressing Colorectal Cancer. Phytochemical Analysis. https://doi.org/10.1002/pca.3495
Vancouver
Sang T, Liang A, Zhou H, Qiu W, Shi L, Zhou H. Integrating UPLC‐MS/MS Bioinformatics and In Vivo Experiments Validation to Elucidate the Mechanism of Wenzi Jiedu Decoction in Suppressing Colorectal Cancer. Phytochemical Analysis. 2025. doi:10.1002/pca.3495
BibTeX
@article{Sang2025,
author = {Sang, Tianqing and Liang, Aoshengxiong and Zhou, Hongli and Qiu, Wenli and Shi, Lijing and Zhou, Hongguang},
title = {Integrating UPLC‐MS/MS Bioinformatics and In Vivo Experiments Validation to Elucidate the Mechanism of Wenzi Jiedu Decoction in Suppressing Colorectal Cancer},
journal = {Phytochemical Analysis},
year = {2025},
doi = {10.1002/pca.3495}
}
EUVIMED